Business Wire

Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani

6.9.2024 21:41:00 EEST | Business Wire | Press release

Share

Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/

Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire)

After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe Kiani with the deepest respect from the global community of families, experts, policymakers, and politicians in patient safety who have greatly benefited from his unwavering commitment to reducing avoidable harm to zero. His partnership with the World Health Organization, his contribution to the Global Patient Safety Action Plan, his outstanding leadership over many years at the Global Ministerial Summits on Patient Safety, and his drive and determination to ensure the ongoing advancement of science and technology across the global medical devices industries have ensured that our patients at every level and in every setting continue to benefit from his latest advances to reduce avoidable harm. The healthcare world is a safer environment because of his dedication, and both patients and healthcare workers will continue to reap the benefits of his excellence for decades to come.”

“I’m honored,” stated Joe Kiani. “The Patient Safety Global Ministerial Summit, the World Health Organization, and Dr. Tedros Adhanom Ghebreyesus have played a leading role in making patient safety a priority around the world. I believe that if we all work together, we have the tools and know-how to create a safer healthcare system for all. To get to zero, we have to implement evidence-based practices, and we need our board members and hospital C-suites demanding their implementation. There is great momentum, and we cannot stop until we reach ZERO preventable harm in our hospitals.”

Since their inception in 2016, the Global Ministerial Summits on Patient Safety have succeeded in raising awareness, as well as creating and sustaining the momentum of the global patient safety movement, as evidenced by the adoption of the WHA resolution (WHA72.6) “Global Action on Patient Safety” in May 2019, which enabled the first-ever World Patient Safety Day in September 2019.

Some of the world’s most prominent leaders in patient safety are presenting at the PSMF’s Summit this year, including Dr. Don Berwick, Senior Fellow at the Institute for Healthcare Improvements. In his keynote, Berwick will discuss how to ensure progress on improvements in patient safety remain at the forefront of the national conversation following last year’s recommendations to the US president in the PCAST report, “A Transformational Effort on Patient Safety.”

During the afternoon session, Dr. Craig Umscheid, Director of the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality (AHRQ), will speak on AHRQ’s National Action Alliance for Patient and Workforce Safety, which takes a systems approach informed by safety self-assessments to improve patient and workforce safety across all healthcare delivery settings, with a goal of reducing harms by 50% from the pandemic peak in two years.

In her keynote, Dr. Michelle Schreiber, Director of Quality Measurement & Value Based Incentives Group, Center for Medicare and Medicaid Services (CMS), will detail the eight goals of CMS’s National Quality Strategy and outline CMS’s efforts to improve healthcare for all by promoting transparency and a safety culture through partnerships, while incentivizing zero harm.

The Summit’s first day will also include presentations from Dr. Diana Ramos, the Surgeon General of California; Dr. Peter Ziese, Head of Medical Innovation & Strategy at PHILIPS; Scott Hamilton Kennedy, an Academy Award-nominated documentary filmmaker; Dr. Evan Benjamin, Associate Professor of Medicine at Harvard Medical School; and Henrietta Hughes, the Patient Safety Commissioner for England.

Panel discussions will focus on advancements in using real-time data from electronic medical records, improving safety through systemwide collaboration, and the essential role hospital boards and the C-suite can play in fostering a culture of safety.

PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906604830/en/

Contacts

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye